Saturday 17 October 2026 Export ASND’s income statement to Excel — free account

Ascendis Pharma A/S

Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024. In the quarter to June 2026, revenue grew 119.9%, EPS grew 612.3%, free cash flow grew 2,335.9% and total debt fell 41.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

225.78 0.84 −0.37%

Follow ASND

Alert me

Market cap: $14.9B
P/E: 16.3×
Fwd P/E: 13.0×
Dividend yield: —
F-score: 5/9
Altman Z: 2.02
Beneish M: −2.51
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.78

Total sells 5.45

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	3	1	—	1	—	—
Sell	—	—	—	—	—	—	1	—	—	—	1	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 14,880.00

Revenue 1,212.10

Net Income 865.91

Free Cash Flow 387.49

Net Debt (421.11)

Current Ratio 2.99

Debt/Equity 0.31

P/E ratio 16.28

Fwd P/E 13.00

P/S ratio 11.99

P/B ratio 8.70

Past 5Y EPS Growth —

This Y EPS Growth 486.85%

Next Y EPS Growth (37.41%)

Next Y revenue growth 68.15%

Next 5Y EPS Growth 38.10%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.18%

10-year low 10-year high

P/B against its own 10 years 66.76%

10-year low 10-year high

EV/Sales against its own 10 years 0.18%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	432	605	697	944
Receivables	60	192	178	261
Inventory	226	320	341	361
Other	—	—	—	—
	761	1,148	1,255	1,617

	2023	2024	2025	Q'26
Payables	102	104	103	121
ST’ Debt	12	532	550	76
Other	81	345	550	329
	214	982	1,210	541

Compound Annual Growth %

	10y	5y	3y
Sales	56.90%	152.47%	147.23%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	289	394	—	—	—
’25	106	179	250	279	815
’24	104	39	64	187	393
’23	36	52	52	149	289
’22	8	7	15	24	54
’21	1	1	1	6	9
’20	2	2	3	1	8

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	328	—	—	—
’25	(15)	(10)	2	84	61
’24	(110)	(65)	(65)	(91)	(331)
’23	(158)	(169)	(135)	(43)	(506)
’22	(147)	(125)	(85)	(166)	(522)
’21	(98)	(139)	(110)	(147)	(494)
’20	(74)	(62)	(76)	(98)	(310)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(18)	324	—	—	—
’25	(16)	(14)	2	80	51
’24	(111)	(64)	(66)	(91)	(332)
’23	(159)	(170)	(136)	(43)	(508)
’22	(147)	(123)	(88)	(170)	(527)
’21	(116)	(131)	(123)	(153)	(523)
’20	(80)	(68)	(78)	(103)	(329)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	11.41	3.29	—	—	—
’25	(1.66)	(0.69)	(1.17)	(0.64)	(4.25)
’24	(2.48)	(2.05)	(1.89)	(0.68)	(7.07)
’23	(2.12)	(2.35)	(3.12)	(1.66)	(9.24)
’22	(2.48)	(1.54)	(3.05)	(3.78)	(10.96)
’21	(1.41)	(3.01)	(1.73)	(2.14)	(8.28)
’20	(1.46)	(2.17)	(2.70)	(3.15)	(9.46)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	11.92	19.60	38.28	59.58	92.00	109.36	61.58	64.33	111.09	118.03	Analyst estimates 2026–2028 Powerpack
	High	21.79	42.00	76.99	140.15	183.98	178.71	137.40	129.43	161.00	229.94
People
People	Employees	101	137	216	330	482	639	797	879	1,017	1,189
	Revenue/emp, $m	0.05	0.01	0.06	0.05	0.02	0.01	0.07	0.33	0.39	0.69
Income, $m
Income, $m	Revenue	5	2	12	15	8	9	54	289	393	815
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	54.71	76.28	83.36	87.83	86.82
	EBT	(76)	(141)	(154)	(244)	(479)	(454)	(609)	(513)	(404)	(241)
	EBT margin, %	(1,492.23)	(8,128.83)	(1,233.25)	(1,631.78)	(6,028.69)	(4,936.26)	(1,129.12)	(177.77)	(102.64)	(29.53)
	Net income	(76)	(140)	(154)	(244)	(479)	(454)	(614)	(521)	(409)	(258)
	Depreciation	1	1	1	7	11	18	19	20	19	20
Per share, $
Per share, $	Revenue	0.19	0.05	0.30	0.32	0.16	0.17	0.96	5.13	6.80	13.44
	Earnings	(2.85)	(4.33)	(3.74)	(5.25)	(9.46)	(8.28)	(10.96)	(9.24)	(7.07)	(4.25)
	Cash flow	(2.51)	(3.20)	(3.99)	(4.24)	(6.13)	(9.02)	(9.31)	(8.99)	(5.72)	1.01
	Capex	(0.03)	(0.03)	(0.08)	(0.12)	(0.37)	(0.52)	(0.09)	(0.05)	(0.01)	(0.16)
	Free cash flow	(2.53)	(3.23)	(4.07)	(4.36)	(6.50)	(9.54)	(9.41)	(9.03)	(5.73)	0.85
	Book value	7.36	6.29	8.05	14.38	18.93	19.09	4.95	(2.80)	(1.98)	(3.04)
	Shares, m	27	34	41	47	51	55	56	56	58	61
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	103.77	773.87	205.98	431.91	1,062.89	800.73	125.55	24.87	20.25	15.86
	P/B	2.71	6.32	7.78	9.67	8.81	7.05	24.40	0.00	0.00	0.00
	EV/Sales	64.62	646.19	179.72	389.93	973.61	725.97	121.11	25.41	21.07	16.22
	EV/FCF	(4.89)	(10.29)	(13.44)	(28.80)	(23.50)	(12.78)	(12.38)	(14.43)	(24.99)	257.17
Cash, $m
Cash, $m	Operating cash flow	(67)	(107)	(164)	(197)	(310)	(494)	(522)	(506)	(331)	61
	Capex	(1)	(1)	(3)	(6)	(19)	(29)	(5)	(3)	(1)	(10)
	Free cash flow	(67)	(109)	(167)	(203)	(329)	(523)	(527)	(508)	(332)	51
Balance, $m
Balance, $m	Working capital	189	204	300	631	785	835	793	547	166	45
	Total debt	—	—	—	41	112	119	536	590	927	986
	Net debt	(200)	(221)	(328)	(629)	(709)	(688)	(239)	158	321	289
	Shareholders’ equity	195	212	331	669	958	1,045	277	(158)	(114)	(184)
Returns, %
Returns, %	ROA	(42.51)	(62.41)	(49.95)	(43.04)	(50.99)	(37.77)	(50.54)	(51.04)	(37.71)	(18.76)
	ROIC	0.00	0.00	(4,420.67)	(397.86)	(94.80)	(93.45)	(968.11)	(84,748.35)	(91.04)	(91.65)
	ROE	(46.08)	(68.81)	(56.66)	(48.86)	(58.84)	(45.30)	(92.90)	(870.08)	300.75	172.80

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
EXEL Exelixis, Inc.	$15.6B	18.8×	16.7×	+10.63% (above 0%: growing)	+25.00% (above 0%: growing)	+557.25% (above 0%: growing)	96.71%	39.51%	Compare
ASND Ascendis Pharma A/S	$14.9B	16.3×	13.0×	+119.88% (above 0%: growing)	n/m	+2,335.93% (above 0%: growing)	91.85%	64.98%
JAZZ Jazz Pharmaceuticals PLC	$13.9B	13.8×	17.3×	+15.55% (above 0%: growing)	n/m	+140.99% (above 0%: growing)	90.37%	20.54%	Compare
HALO Halozyme Therapeutics, Inc.	$13.8B	34.6×	10.6×	+47.67% (above 0%: growing)	+44.12% (above 0%: growing)	+141.18% (above 0%: growing)	83.54%	59.80%	Compare
BBIO BridgeBio Pharma, Inc.	$13.1B	— (loss-making)	— (loss-making)	+120.39% (above 0%: growing)	n/m	+16.59% (above 0%: growing)	93.83%	(43.94%)	Compare
CORT Corcept Therapeutics Incorporated	$12.3B	212×	139×	+31.74% (above 0%: growing)	+21.21% (above 0%: growing)	−29.89% (below 0%: shrinking)	98.41%	16.12%	Compare
SMMT Summit Therapeutics PLC	$12.3B	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−112.80% (below 0%: shrinking)	0.00%	0.00%	Compare
TECH Bio-Techne Corp	$11.4B	62.0×	37.6×	+1.33% (above 0%: growing)	n/m	−6.83% (below 0%: shrinking)	65.82%	23.13%	Compare
BMRN BioMarin Pharmaceutical Inc.	$10.9B	144×	16.1×	+19.91% (above 0%: growing)	−81.60% (below 0%: shrinking)	−20.28% (below 0%: shrinking)	79.51%	11.21%	Compare
Median of peers	$12.7B	48.3×	17.0×	+17.73%	+23.11%	+4.88%	86.96%	18.33%

All 614 Biotechnology stocks →

Ascendis Pharma A/S (ASND) key facts

Concern: Ascendis Pharma A/S reported a net loss of $258.0 million, or a loss of $4.25 per share, for fiscal 2025.
Strength: Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.
Ascendis Pharma A/S (ASND) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, ASND traded at $225.78, a market capitalization of $14.9 billion.
At that price the stock trades at 16.3× trailing-twelve-month earnings and 12.0× sales.
Return on equity was 172.8% and debt-to-equity 0.31.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 2.02 (grey zone) for fiscal 2025.